WallStreetZenWallStreetZen

NASDAQ: SPPI
Spectrum Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for SPPI

Based on 2 analysts offering 12 month price targets for Spectrum Pharmaceuticals Inc.
Min Forecast
$1.00+116.92%
Avg Forecast
$2.50+442.3%
Max Forecast
$4.00+767.68%

Should I buy or sell SPPI stock?

Based on 2 analysts offering ratings for Spectrum Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SPPI stock forecasts and price targets.

SPPI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 22%
79
BuyMaintains$4.00+767.68%2022-11-28
B. Riley Securities
Top 1%
100
HoldDowngrades$1.00+116.92%2022-11-16

1 of 1

Forecast return on equity

Is SPPI forecast to generate an efficient return?
Company
391.09%
Industry
15.35%
Market
62.84%
SPPI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SPPI forecast to generate an efficient return on assets?
Company
117.9%
Industry
13.55%
SPPI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SPPI earnings per share forecast

What is SPPI's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.54
Avg 2 year Forecast
-$0.16
Avg 3 year Forecast
$0.29

SPPI revenue forecast

What is SPPI's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$4.2M
Avg 2 year Forecast
$129.7M
Avg 3 year Forecast
$252.9M

SPPI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPPI$0.46$2.50+442.30%Buy
TNYA$2.29$24.67+977.16%Strong Buy
SPRO$1.83$5.25+186.89%Buy
GNTA$5.21$23.00+341.46%Strong Buy
KRON$1.67$10.75+543.71%Strong Buy

Spectrum Pharmaceuticals Stock Forecast FAQ

Is Spectrum Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SPPI) stock is to Buy SPPI stock.

Out of 2 analysts, 0 (0%) are recommending SPPI as a Strong Buy, 1 (50%) are recommending SPPI as a Buy, 1 (50%) are recommending SPPI as a Hold, 0 (0%) are recommending SPPI as a Sell, and 0 (0%) are recommending SPPI as a Strong Sell.

If you're new to stock investing, here's how to buy Spectrum Pharmaceuticals stock.

What is SPPI's earnings growth forecast for 2022-2024?

(NASDAQ: SPPI) Spectrum Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.

Spectrum Pharmaceuticals's earnings in 2022 is -$106,130,000.On average, 4 Wall Street analysts forecast SPPI's earnings for 2022 to be -$109,730,975, with the lowest SPPI earnings forecast at -$119,891,251, and the highest SPPI earnings forecast at -$101,602,755. On average, 4 Wall Street analysts forecast SPPI's earnings for 2023 to be -$32,512,882, with the lowest SPPI earnings forecast at -$71,121,929, and the highest SPPI earnings forecast at -$6,096,165.

In 2024, SPPI is forecast to generate $58,929,598 in earnings, with the lowest earnings forecast at -$24,384,661 and the highest earnings forecast at $113,795,086.

What is SPPI's revenue growth forecast for 2022-2024?

(NASDAQ: SPPI) Spectrum Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.69%.

Spectrum Pharmaceuticals's revenue in 2022 is $0.On average, 3 Wall Street analysts forecast SPPI's revenue for 2022 to be $845,944,538, with the lowest SPPI revenue forecast at $304,808,265, and the highest SPPI revenue forecast at $1,461,047,617. On average, 3 Wall Street analysts forecast SPPI's revenue for 2023 to be $26,347,626,427, with the lowest SPPI revenue forecast at $18,471,380,859, and the highest SPPI revenue forecast at $32,147,111,682.

In 2024, SPPI is forecast to generate $51,394,737,589 in revenue, with the lowest revenue forecast at $33,528,909,150 and the highest revenue forecast at $66,996,856,647.

What is SPPI's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: SPPI) forecast ROA is 117.9%, which is higher than the forecast US Biotechnology industry average of 13.55%.

What is SPPI's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SPPI price target, the average SPPI price target is $2.50, with the highest SPPI stock price forecast at $4.00 and the lowest SPPI stock price forecast at $1.00.

On average, Wall Street analysts predict that Spectrum Pharmaceuticals's share price could reach $2.50 by Nov 28, 2023. The average Spectrum Pharmaceuticals stock price prediction forecasts a potential upside of 442.3% from the current SPPI share price of $0.46.

What is SPPI's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: SPPI) Spectrum Pharmaceuticals's current Earnings Per Share (EPS) is -$0.62. On average, analysts forecast that SPPI's EPS will be -$0.54 for 2022, with the lowest EPS forecast at -$0.59, and the highest EPS forecast at -$0.50. On average, analysts forecast that SPPI's EPS will be -$0.16 for 2023, with the lowest EPS forecast at -$0.35, and the highest EPS forecast at -$0.03. In 2024, SPPI's EPS is forecast to hit $0.29 (min: -$0.12, max: $0.56).

What is SPPI's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: SPPI) forecast ROE is 391.09%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.